Evidence map›Paper›PMID 38380974›Full record

ArticleActa dermato-venereologica2024

Patient Preferences in the Treatment of Moderate-to-severe Atopic Dermatitis.

Mahreen Ameen, Raed Alhusayen, Henrik Brandi, Mette Bøgelund, Henrik H Jensen, Signe B Reitzel, Jacob P Thyssen

Open access · goldAbstract read
In one paragraph

Article in Acta dermato-venereologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. [Biologics and infections: treat and prevent].Dermatologie (Heidelberg, Germany) · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Mahreen AmeenRoyal free London NHS Foundation Trust, London, United Kingdom.
Raed AlhusayenSunnybrook Health Sciences Centre, Division of Dermatology, Toronto, Canada.
Henrik BrandiLEO Pharma A/S, Ballerup, Denmark. HEBRD@leo-pharma.com.
Mette BøgelundEY Economics Denmark, Frederiksberg, Denmark.
Henrik H JensenEY Economics Denmark, Frederiksberg, Denmark.
Signe B ReitzelEY Economics Denmark, Frederiksberg, Denmark.
Jacob P ThyssenLEO Pharma A/S, Ballerup, Denmark; Bispebjerg Hospital, Department for Dermatology, Copenhagen, Denmark.
Bispebjerg Hospital · DKLeo Pharma (Denmark) · DKRoyal Free London NHS Foundation Trust · GBSunnybrook Health Science Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atopic dermatitis is a chronic, inflammatory skin disease. A variety of systemic treatments are available for patients with moderate-to-severe atopic dermatitis. The efficacy, safety and administration profile of these treatments vary, and determining the optimal treatment strategy may require weighing the benefits and drawbacks of therapies with diverse characteristics. This study used an online discrete choice experiment survey to investigate treatment preferences among adults with atopic dermatitis from Denmark, France, the UK, or Canada. Participants were identified through existing online panels. The survey included questions regarding different treatment attributes, defined based on currently approved treatments for moderate to severe atopic dermatitis. Treatment preferences were measured as the relative importance of different treatment attributes. A total of 713 respondents met the inclusion criteria and completed the survey. The discrete choice experiment identified a significant preference for avoiding the risk of severe adverse events, and for oral pill every day compared with biweekly injections. The time to full effect was not rated as being important. These findings suggest that patients with moderate-to-severe atopic dermatitis prioritize safety as most important, followed by ease of administration in their treatment preferences, while time to full effect and monitoring requirements were the least important attributes.

Indexed as

Dermatitis, AtopicAdministration, CutaneousAdultHumansPatient PreferenceSurveys and QuestionnairesTreatment Outcome

Identifiers

PMID38380974
PMCPMC10910525
OpenAlexW4392019044

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.